We support latest Emmerdale storyline on Faith Dingle's Secondary Breast Cancer diagnosis
Catherine Priestley, Clinical Nurse Specialist at Breast Cancer Now, said:
17 May 2022
We respond to new research into how salt in tumours could help diagnose and treat breast cancer
New research, funded by Breast Cancer Now and Cancer Research UK at the universities of York and Cambridge, has shown that analysing sodium levels in breast cancer tumours can give an accurate indication of how aggressive a cancer is - and whether chemo treatments are taking effect.
25 Apr 2022
We respond to NICE provisional decision not to recommend alpelisib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
01 Apr 2022
We respond to research about artificial sweeteners and breast cancer risk
Commenting on research published in PLOS Medicine about artificial sweeteners and breast cancer risk, Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
24 Mar 2022
We respond to new data from major trial OlympiA shows adjuvant olaparib improved survival in patients
On 16 March new findings from the OlympiA phase III trial were presented at a virtual plenary session from the European Society for Medical Oncology.
16 Mar 2022
We respond to NHS England breast cancer waiting times: January 2022
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
10 Mar 2022
We respond to NHS England's proposed new standards
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
09 Mar 2022
Breast Cancer Now responds to NICE provisional decision not to recommend pembrolizumab (Keytruda) in combination with chemotherapy (paclitaxel or nab-paclitaxel)
08 Mar 2022
Breast Cancer Now welcomes SMC decision to recommend Trodelvy for use on the NHS in Scotland
07 Mar 2022
We respond to NICE decision to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to recommend breast cancer treatment tucatinib with trastuzumab and capecitabine for routine use on the NHS in England, for treating HER2 positive, locally advanced or secondary breast cancer after at least two prior anti-HER2 treatment regimens.
25 Feb 2022
We respond to today's NHSE Breast Screening Programme 2020-21 report
Key findings: In 2020/21, around 936,000 fewer women in England were screened for breast cancer compared to the previous year. This is a decrease of 44%. In 2020/21, screening uptake reached an all-time low of 61.8%. This was a 7.3% decrease on the previous year. Regional uptake varied from 54.1% in London, to 65% in the East Midlands and the Southeast.
24 Feb 2022
We respond to the latest COVID-19 guidance
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
22 Feb 2022